Atlanta Braves designated hitter Jurickson Profar is facing a 162-game suspension after testing positive for performance-enhancing drugs for the second time in the past year, according to multiple reports. The penalty, which would equal a full regular-season schedule, stems from Major League Baseball’s policy on repeat violations of its Joint Drug Prevention and Treatment Program.
Because this is Profar’s second positive test within a 12-month span, the disciplinary framework calls for a substantially longer ban than a first offense. A 162-game suspension would effectively sideline the veteran switch-hitter for an entire season, pending any appeals process or official announcement from the league. Details on the specific substance involved in the most recent test have not been made public.
Profar, who has played multiple positions throughout his career but was expected to serve primarily as a designated hitter for Atlanta, had been projected to contribute as a versatile bat in the lineup. The Braves, a club with postseason aspirations and a deep offensive core, now face the prospect of moving forward without him for the duration of the suspension. The team has not publicly outlined its contingency plans for replacing his role on the roster or in the batting order.
Major League Baseball’s drug program includes escalating penalties for repeated violations, with the goal of deterring the use of banned substances and maintaining competitive integrity. A full-season ban is among the most severe penalties available under the current agreement between MLB and the MLB Players Association. Players serving suspensions for performance-enhancing drug offenses are ineligible to play in major league games during the suspension and may face additional limitations related to roster status.
As of now, the suspension has not been formally detailed beyond the reported length and the fact that it represents Profar’s second violation in the past year. Any potential appeal, statement from Profar, or formal comment from the Braves or MLB had not been publicly disclosed at the time of the report. Further developments will likely clarify the official start date of the suspension, how it will be applied to the schedule, and what it means for Profar’s future opportunities at the major league level.
Profar’s situation adds another high-profile case to the ongoing enforcement of MLB’s drug policy. The outcome of this process will be closely watched around the league, as teams, players, and fans continue to navigate the consequences and implications of performance-enhancing drug violations in professional baseball.
